Biologics Are Transforming the WAIHA Market
Biologics are revolutionising the treatment of warm autoimmune hemolytic anemia (WAIHA), offering new options for patients who do not respond adequately to traditional therapies such as corticosteroids and immunosuppressants. Rituximab, a monoclonal antibody targeting CD20, has become a standard second-line therapy for WAIHA, demonstrating significant efficacy in reducing hemolysis and...
0 Kommentare 0 Geteilt 2 Ansichten 0 Bewertungen